Imaging company Lantheus enters therapeutics with Progenics takeout

Lantheus plans to acquire Progenics in an all-stock deal, creating a path for the medical imaging company to move into therapeutics.

Based on the 86.4 million outstanding shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) and the

Read the full 342 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE